Mobile

A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associated w...

Update Il y a 4 ans
Reference: EUCTR2004-004857-24

A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associated with Age-related Macular Degeneration

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine the ocular and systemic safety of AG-013958 Suspension for Injection for 13 weeks following administration of a single ST injection and for 104 weeks following multiple administrations by ST injection. To determine the efficacy of AG-013958 Suspension for Injection in subjects with age-related macular degeneration as assessed by visual acuity at 52 weeks.

Inclusion criteria

  • Age-related macular degeneration

Links